公开(公告)号：US20130323229A1

公开(公告)日：2013-12-05

申请号：US13906171

申请日：2013-05-30

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Paola Leone ,  Jeremy Francis

IPC: A61K38/50 ,  C12N15/86

CPC classification number: A61K38/50 ,  A61K35/30 ,  A61K38/52 ,  C12N15/86 ,  C12N2750/14141 ,  C12Y305/01015

Abstract: The present invention provides a novel method of treatment for treating brain disorders that manifest oxidative stress by providing targeted populations of neurons with the ability to catabolize the acetylated amino acid derivative, N-acetylaspatic acid (NAA) and further supply extraphysiological levels of ATP to neurons via the targeted expression of the NAA catabolic enzyme aspartoacylase (ASPA) in neurons and astrocytes.

Abstract translation: 本发明提供了一种新的治疗方法，用于通过提供具有分解代谢乙酰化氨基酸衍生物N-乙酰丙酸（NAA）的能力的神经元的目标群体来治疗表现出氧化应激的脑疾病，并进一步向神经元提供ATP的形态学上的水平 通过NAA分解代谢酶天冬酰胺酶（ASPA）在神经元和星形胶质细胞中的靶向表达。

公开(公告)号：US20130131313A1

公开(公告)日：2013-05-23

申请号：US13735253

申请日：2013-01-07

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Alexey G. Ryazanov ,  Benjamin E. Turk

IPC: C07K7/08

CPC classification number: C07K7/08 ,  C07D487/04

Abstract: Assays for identifying novel compounds for inhibiting eEF2 kinase and consequence peptides employed therein.

Abstract translation: 鉴定用于抑制eEF2激酶的新化合物及其中使用的后果肽的测定。

公开(公告)号：US20130131005A1

公开(公告)日：2013-05-23

申请号：US13668897

申请日：2012-11-05

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Stephen F. Vatner ,  Dorothy E. Vatner

IPC: A61K31/7076

CPC classification number: A61K31/7076

Abstract: The invention provides a method of reducing infarct size and/or limiting, decreasing and/or inhibiting reperfusion injury and/or ameliorating heart failure in a patient comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to the patient. The compound capable of inhibiting AC5 is particularly effective when administered during or after reperfusion in patients suffering from an ischemic injury.

Abstract translation: 本发明提供了一种降低梗死面积和/或限制，减少和/或抑制患者的再灌注损伤和/或改善心力衰竭的方法，包括向患者施用药学有效量的至少一种能够抑制AC5的化合物。 能够抑制AC5的化合物在再灌注期间或之后在患有缺血性损伤的患者中施用时特别有效。

公开(公告)号：US20130022501A1

公开(公告)日：2013-01-24

申请号：US13621552

申请日：2012-09-17

Applicant: University of Medicine and Dentistry of New Jerse

Inventor： Daniel H. Fine ,  David Furgang

IPC: G01N21/64

CPC classification number: G01N33/6863 ,  G01N33/582 ,  G01N33/6893 ,  G01N2333/285 ,  G01N2333/523 ,  G01N2800/108 ,  G01N2800/18

Abstract: The present invention is directed to methods to detect and diagnose osteoporosis and periodontal disease using salivary biomarkers.

Abstract translation: 本发明涉及使用唾液生物标志物检测和诊断骨质疏松症和牙周病的方法。

公开(公告)号：US20140234258A1

公开(公告)日：2014-08-21

申请号：US14226990

申请日：2014-03-27

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Masayori Inouye ,  Junjie Zhang ,  Yong Long Zhang

IPC: C12N9/22

CPC classification number: C12N9/22 ,  A61K38/465 ,  C12N15/70 ,  C12P19/34 ,  C12Q1/42 ,  C12Q1/44 ,  G01N2333/922 ,  G01N2800/26

Abstract: The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to advantage. The invention also encompasses screening methods to identify compounds/agents capable of modulating mRNA interferase activity and methods for using such compounds/agents. Also provided is a kit comprising mRNA interferase nucleic and/or amino acid sequences, mRNA interferase activity compatible buffers, and instruction materials.

Abstract translation: 本发明涉及在本文中称为表达内切核糖核酸酶活性的mRNA干扰酶的新型家族的发现。 因此，本发明人的新发现提出了可以使用mRNA干扰酶核酸和氨基酸序列及其组合物的新用途。 本发明还包括鉴定能够调节mRNA干扰酶活性的化合物/试剂的筛选方法以及使用这些化合物/试剂的方法。 还提供了包含mRNA干扰酶核酸和/或氨基酸序列，mRNA干扰酶活性相容缓冲液和说明材料的试剂盒。

公开(公告)号：US20140031933A1

公开(公告)日：2014-01-30

申请号：US13836607

申请日：2013-03-15

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Charles J. Gatt ,  Aaron S. Merriam ,  Michael G. Dunn

IPC: A61F2/38

CPC classification number: A61F2/442 ,  A61F2/30756 ,  A61F2/3094 ,  A61F2/38 ,  A61F2/3872 ,  A61F2/4261 ,  A61F2/44 ,  A61F2002/30062 ,  A61F2002/30112 ,  A61F2002/30116 ,  A61F2002/30757 ,  A61F2002/30761 ,  A61F2002/30762 ,  A61F2002/30766 ,  A61F2002/4435 ,  A61F2002/4445 ,  A61F2002/4495 ,  A61F2310/00371 ,  A61F2310/00383 ,  A61F2310/00982 ,  A61F2310/00994 ,  Y10T156/10

Abstract: A meniscus implant including a c-shaped scaffold having an arcuate middle section extending between an anterior end and a posterior end. A reinforcing network of fibers independent from the scaffold is embedded therein. Fibers of said network fibers exit each end of the scaffold to form respective anterior and posterior attachment segments which extend parallel to a central axis of the scaffold. The network of fibers is configured to convert an axial compressive force on said scaffold to tensile loads on said attachment points.

Abstract translation: 一种弯液面植入物，其包括具有在前端和后端之间延伸的弓形中间部分的c形支架。 嵌入独立于支架的纤维的加强网络。 所述网络纤维的纤维离开支架的每个端部以形成平行于支架的中心轴线延伸的相应的前部和后部附接段。 纤维网构造成将所述支架上的轴向压缩力转换成所述附接点上的拉伸载荷。

公开(公告)号：US20130225597A1

公开(公告)日：2013-08-29

申请号：US13872525

申请日：2013-04-29

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Isaac Yi Kim ,  Matthew C. Ercolani

IPC: A61K9/00 ,  A61K31/519

CPC classification number: A61K9/0014 ,  A61K31/497 ,  A61K31/519 ,  A61K47/38

Abstract: The present invention is a method for treating post-radical prostatectomy erection dysfunction in a patient using a PDE-4, PDE-5, PDE-6 and/or PDE-7 inhibitor, wherein said PDE inhibitor is delivered at the incision site via an adhesion barrier.

Abstract translation: 本发明是一种使用PDE-4，PDE-5，PDE-6和/或PDE-7抑制剂治疗患者的根治前前列腺切除术勃起功能障碍的方法，其中所述PDE抑制剂在切口部位经由 粘附屏障。

公开(公告)号：US20130210872A1

公开(公告)日：2013-08-15

申请号：US13768544

申请日：2013-02-15

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Atif Jalees Khan ,  Suzie Chen ,  James S. Goydos ,  Bruce G. Haffty

IPC: A61K41/00

CPC classification number: A61K41/0038

Abstract: Disclosed is a method of treating a tumor in a patient, comprising (a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and (b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth. The method can further comprise administering an effective amount of one or more additional therapeutic agents.

Abstract translation: 本发明公开了一种治疗患者肿瘤的方法，其包括（a）以有效使肿瘤细胞对电离辐射敏感的量给予利鲁唑，和（b）以有效减少肿瘤细胞的剂量用电离辐射照射肿瘤细胞 成长。 该方法可以进一步包括施用有效量的一种或多种另外的治疗剂。

公开(公告)号：US20130183669A1

公开(公告)日：2013-07-18

申请号：US13790309

申请日：2013-03-08

Applicant: University of Medicine and Dentistry of New Jersey ,  Rutgers, The State University

Inventor： James H. Millonig ,  Linda Brzustowicz ,  Neda Gharani

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q2600/156

Abstract: Mutations located within the gene encoding the homeobox transcription factor, ENGRAILED 2 (EN2), have now been identified as molecular markers associated with susceptibility for autism and related disorders. Thus, the present invention relates to compositions in the form of diagnostic kits, primers and target sequences, for use in methods for determining the predisposition, the onset or the presence of autism spectrum disorder in a mammal. Moreover, therapeutic methods for treating a person inflicted with, or predisposed to, an autism spectrum disorder based upon modulating the level or activity of EN2 are also provided.

Abstract translation: 位于编码同源框转录因子（ENGRAILED 2）（EN2）的基因内的突变现已被鉴定为与自闭症和相关疾病易感性相关的分子标记。 因此，本发明涉及诊断试剂盒，引物和靶序列形式的组合物，其用于确定哺乳动物自闭症谱系障碍的倾向性，发病或存在的方法。 此外，还提供了用于治疗基于调节EN2的水平或活性而导致或倾向于自闭症谱系障碍的人的治疗方法。

公开(公告)号：US20130109035A1

公开(公告)日：2013-05-02

申请号：US13648921

申请日：2012-10-10

Applicant: University of Medicine and Dentistry of New Jersey

Inventor： Kiron M. Das ,  Koushik K. Das ,  Mari Mino-Kenudson

IPC: G01N33/68

CPC classification number: G01N33/57438 ,  G01N33/6893 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention relates to diagnostic, prognostic and clinical methods of distinguishing high-risk IPMN from more benign IPMN as well as high-grade PanIN and PDAC from low-grade PanIN with moderate sensitivity and very high specificity using Das-1 and related antibodies.

Abstract translation: 本发明涉及使用Das-1和相关抗体，从中等敏感性和非常高的特异性的低等级PanIN区分高风险IPMN与更良性IPMN以及高级PanIN和PDAC的诊断，预后和临床方法。